A sizeable number of working adults suffer from major depressive disorder (MDD) and treatment-resistant depression (TRD ) which impacts their quality of life and work productivity. Standard workplace mental health support comprises disease management programs, EAPs and behavioral managed health organizations. However, these solutions may not be adequate to support individuals suffering from TRD. Ketamine-Assisted Therapy (KAT) is currently being utilized as a legal treatment for TRD, and research continues to explore its efficacy when other treatments have failed. This action brief covers what employers need to know to enable safe, effective and affordable access of KAT for TRD, and includes the financial impacts, a mental health savings calculator, questions to ask your vendors and employer action steps.